DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Rick Pauls - President & Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Etzer Darout - Guggenheim Partners Francois Brisebois - Oppenheimer & Co. Inc. Thomas Flaten - Lake Street Capital Markets, LLC Elemer Piros - ROTH Capital Partners Jason McCarthy - Maxim Group, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐ For the transition period from _ ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2020 Results Earnings Conference Call March 11, 2021 8:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Etzer Darout - Guggenheim Elemer Piros - ROTH Capital Partners Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Fourth Quarter 2020 Conference Call. An audio re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission file number: 001-36291 DIAMEDICA THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Britis ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2020 Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Rick Pauls - President & CEO Scott Kellen - CFO Harry Alcorn - Chief Medical Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2020 Conference Call. An audio recording of the webcast will be available shortly after t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2020 Earnings Conference Call August 12, 2020 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2020 Financial Results Conference Call. An au ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ Title of each class Trading Symbol Name of each exchange on which registered Voting common shares, no par value per share DMAC The Nasdaq Stock Market LLC FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2020 Results Earnings Conference Call May 14, 2020 8:00 AM ET Company Participants Rick Pauls - President, Chief Executive Officer Scott Kellen - Chief Financial Officer Harry Alcorn - Chief Medical Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Thomas Flaten - Lake Street Capital Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Conference Call to discuss the topline results from DiaMedica's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to __________________. Commission File Number: 001-36291 ____________________ DIAMEDICA THERAPEUTICS INC. (Exa ...